An exploratory study of administration of foscarnet for cytomegalovirus infection and human herpes virus type 6 infection after hematopoietic stem cell transplantation..
Not Applicable
- Conditions
- Cytomegalovirus infection and human herpes virus type 6 infection after hematopoietic stem cell transplantation
- Registration Number
- JPRN-UMIN000003041
- Lead Sponsor
- niversity of Tokyo Hospital, Depaartment of Hematology and Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. Allergy to foscarnet. 2. The creatinine clearance is less than 0.4mL/min/kg. 3. HIV-positive patients. 4. A woman during pregnancy or potential pregnancy. 5. Patients who are recognized as inadaptable for this trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in viral load at the end of treatment.
- Secondary Outcome Measures
Name Time Method Changes in the symptoms of viral infection at the end of treatment. Survival at two months after the end of treatment. Re-administration of antiviral drugs within two months after the end of treatment. Adverse events.